

Accepted Manuscript

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Michael Charlton, Edward Gane, Michael P. Manns, Robert S. Brown Jr., Michael P. Curry, Paul Y. Kwo, Robert J. Fontana, Richard Gilroy, Lewis Teperman, Andrew J. Muir, John G. McHutchison, William T. Symonds, Diana Brainard, Brian Kirby, Hadas Dvory-Sobol, Jill Denning, Sarah Arterburn, Didier Samuel, Xavier Forns, Norah A. Terrault

PII: S0016-5085(14)01194-9
DOI: [10.1053/j.gastro.2014.10.001](https://doi.org/10.1053/j.gastro.2014.10.001)
Reference: YGAST 59370

To appear in: *Gastroenterology*
Accepted Date: 2 October 2014

Please cite this article as: Charlton M, Gane E, Manns MP, Brown Jr RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir, AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA, Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation, *Gastroenterology* (2014), doi: 10.1053/j.gastro.2014.10.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in *Gastroenterology* are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.



**Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus
Infection After Liver Transplantation**

Short title: Sofosbuvir and Ribavirin in Post-Transplant HCV

Michael Charlton¹, Edward Gane², Michael P. Manns³, Robert S. Brown Jr⁴,
Michael P. Curry⁵, Paul Y. Kwo⁶, Robert J. Fontana⁷, Richard Gilroy⁸, Lewis Teperman⁹,
Andrew J. Muir¹⁰, John G. McHutchison¹¹, William T. Symonds¹¹, Diana Brainard¹¹, Brian
Kirby¹¹, Hadas Dvory-Sobol¹¹, Jill Denning¹¹, Sarah Arterburn¹¹, Didier Samuel¹², Xavier
Forns¹³, Norah A. Terrault¹⁴

From the ¹Mayo Clinic, Rochester, MN; ²Auckland City Hospital, Auckland, New Zealand;

³Hannover Medical School, Hannover, Germany; ⁴Columbia University, New York, NY;

⁵Beth Israel Deaconess Medical Center, Boston, MA; ⁶Indiana School of Medicine, Indianapolis,

IN; ⁷University of Michigan, Ann Arbor, MI; ⁸Kansas University Medical Center, Kansas City,

KS; ⁹NYU Medical Center, New York, NY; ¹⁰Duke University Medical Center, Durham, NC;

¹¹Gilead Sciences, Foster City, CA; ¹²AP-HP Hôpital Paul Brousse, Centre Hépatobiliaire, and
Université Paris Sud, Villejuif, France; ¹³Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD,

Barcelona, Spain; and ¹⁴University of California at San Francisco, San Francisco, CA

EudraCT Number: 2012-002417-19; **ClinicalTrials.gov number:** NCT01687270

Address correspondence to: Michael Charlton, MD; michael.charlton@imail.org

Download English Version:

<https://daneshyari.com/en/article/6094148>

Download Persian Version:

<https://daneshyari.com/article/6094148>

[Daneshyari.com](https://daneshyari.com)